Showing 1401-1410 of 1601 results for "".
- Allergan Completes Acquisition of Kybella Maker Kytherahttps://practicaldermatology.com/news/allergan-completes-acquisition-of-kybella-maker-kythera/2458856/Allergan plc has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion. The acquisition of Kythera adds Kybella® (deoxych
- Dermira: Kathleen Sebelius Elected to Board of Directorshttps://practicaldermatology.com/news/dermira-kathleen-sebelius-elected-to-board-of-directors/2458861/Dermira, Inc. has elected Kathleen Sebelius, the 21st U.S. Secretary of Health and Human Services, to its board of directors. "We are honored and excited to welcome Kathleen Sebelius to Dermira's board of directors,&quo
- Scleroderma Foundation to Honor Genentech's Dr. Jeffrey Siegel for Scientific Contributionshttps://practicaldermatology.com/news/scleroderma-foundation-to-honor-genentechs-dr-jeffrey-siegel-for-scientific-contributions/2458864/Dr. Jeffrey Siegel, Senior Group Medical Director of Immunology at Genentech, will be honored by the Scleroderma Foundation of Southern California with the Spirit of Leadership Award at their 17th annual “Key to a Cure” gala, which will be held on Saturday, Octobe
- ASDS/ASDSA Accepts 'Call to Action' on Skin Cancer Preventionhttps://practicaldermatology.com/news/asdsasdsa-accepts-call-to-action-on-skin-cancer-prevention/2458883/The American Society for Dermatologic Surgery (ASDS) announced it actively supports the measures to fight skin cancer set forth in the Skin Cancer Prevention Progress Report that was recently issued by the Centers for Disease Control and Prevention. The Progress Report builds upon last su
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- Court Rules in Favor of Amarin Corp. in "Off-label" Disputehttps://practicaldermatology.com/news/court-rules-in-favor-of-amarin-corp-in-off-label-dispute/2458897/Amarin Corporation plc (NASDAQ: AMRN) today announced a United States District Court has ruled that Amarin may promote to healthcare professionals certain uses of Amarin'slead product, Vascepa®(icosapent ethyl) c
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aestheti
- Neutrogena Sunscreens Awarded NEA Seal of Acceptancehttps://practicaldermatology.com/news/neutrogena-sunscreens-awarded-nea-seal-of-acceptance/2458928/The National Eczema Association (NEA) awarded its Seal of Acceptance to five Neutrogena sunscreens. This recognition is given to product innovations that help improve the quality of life for people with eczema, empowering consumers to make informed eczema purchase decisions. The fol
- Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine Ahttps://practicaldermatology.com/news/immune-pharmaceuticals-expands-immuno-dermatology-development-portfolio-with-topical-nano-formulated-cyclosporine-a/2458932/Immune Pharmaceuticals Inc. entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclospo